

## Sodium citrotartrate granules for urinary symptom relief

SESLHDPR/474

### POLICY STATEMENT

The Registered Nurse (RN) / Registered Midwife (RM) is authorised to instigate nurse/midwife-initiated medication without an authorised prescriber's order under the specific circumstances set out in the **INDICATIONS** section and provided there are no contraindications present.

It is important for nursing and midwifery staff to remain aware that:

- Minor ailments may be symptoms of other more serious diseases or may be adverse reactions to medication already prescribed
- Nurse-initiated medication may interact with the patient's prescribed medication
- The maximum daily recommended dose of the medication must not be exceeded<sup>1</sup>

The administering nurse/midwife must record the administration on an approved paper or electronic medication chart, clearly indicating that the medicine was nurse initiated.

If the patient continues to require the medication (i.e., more than two doses in 24 hours) then a medical officer (MO) must be consulted and a regular or PRN order obtained.

A change in the patient's condition such as newly occurring or increasing severity of symptoms must be reported to the MO and investigated.

### INDICATIONS

Urinary alkalinisation for relief of urinary symptoms in patients over 12 years of age

### CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients.  
Renal failure or hypernatraemia.  
Concurrent hexamine mandelate or hexamine hippurate treatment  
Concurrent quinolone antibiotic treatment

### PRECAUTIONS

Low sodium diet - preparation contains sodium 644 mg/sachet  
Use cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary oedema and pre-eclampsia.  
Use in pregnancy has not been studied.  
Caution in breastfeeding

### HISTORY/ASSESSMENT

Evaluate clinical condition of the patient including laboratory determinations (e.g. serum electrolytes, acid/ base balance), particularly in patients with renal disease.

## Sodium citrotartrate granules for urinary symptom relief

**SESLHDPR/474**

### PROTOCOL/ADMINISTRATION GUIDELINES

| Caution: CHECK for allergies and/or contraindications  |   |             |             |
|--|---|-------------|-------------|
| Drug   | Dose  | Route       | Frequency   |
| <b>Sodium citrotartrate granules</b><br><br>sodium bicarbonate 1.76 g +<br>sodium citrate 630 mg + citric<br>acid 720 mg + tartaric acid 890<br>mg powder for oral liquid, 4 g<br>sachet | <b>Children over 12 years:</b><br><b>ONE sachet</b> | <b>Oral</b> | <b>Once</b> |
|  | <b>Adults:</b><br><b>ONE to TWO sachets</b>         |             |             |
| Dissolve contents of sachet(s) in a glass of cold water  |   |             |             |

### MONITORING - POTENTIAL ADVERSE EFFECTS/INTERACTIONS

**Adverse effects:** Mild laxative effects

**Interactions:** Hexamine mandelate or hexamine hippurate, quinolone antibiotics, antacids. Alkalisiation of the urine may result in a decreased therapeutic effect of lithium, salicylates and tetracyclines.

Alkalisiation of the urine may result in an increased therapeutic effect of amphetamines, ephedrine/ pseudoephedrine.

### DOCUMENTATION

A record of the administration must be made on the approved paper or electronic medication chart noting that the medication was nurse initiated.

A further record of the medication administered including indication, dose and effect must be included in the patient's health care record.

### PRACTICE POINTS

- Encourage patient to drink plenty of fluids

### REFERENCES/FURTHER READING

1. [NSW Health Policy Directive Medication Handling PD2022\\_032](#)
2. [MIMs Online](#). Ural. 01 February 2006.
3. [Australian Medicines Handbook](#). Urinary alkinisation and acidification. January 2023.

**Sodium citrotartrate granules for urinary  
symptom relief**

**SESLHDPR/474**

**REVISION and APPROVAL HISTORY**

| <b>Date</b>    | <b>Version Number</b> | <b>Author and Approval</b>   |
|----------------|-----------------------|--|
| July 2015      | DRAFT                 | Pharmacy Department, Prince of Wales Hospital  |
| September 2015 | 1                     | Approved by SESLHD Drug & QUM Committee  |
| May 2018       | DRAFT 2               | Reviewed by nursing and pharmacy staff. Minor wording updates made. Brand names removed. References updated. |
| July 2018      | 2                     | Approved by SESLHD Quality Use of Medicines Committee  |
| August 2021    | DRAFT 3               | Reviewed by nursing and pharmacy staff. No changes required.   |
| September 2021 | 3                     | Approved by SESLHD Quality Use of Medicines Committee  |
| June 2023      | DRAFT 4               | NSW Medicines Formulary reviewed. Reviewed by nursing and pharmacy staff.                                    |
| September 2023 | 4                     | Approved by SESLHD Drug and Therapeutics Committee   |